retatrutide fda approval status 2024 Retatrutide, an experimental weight-loss drug, has not been approved by the FDA. But, doctors and nurse practitioners in clinics across the country are prescribing it anyway, a CBS News investigation found. @adamyamaguchi Retatrutide produces up to 30.3%

The simplest way to keep them straight is by counting receptors: semaglutide acts on one (GLP-1), tirzepatide on two (GLP-1 and GIP), and retatrutide on three (GLP-1, GIP, and glucagon)

However, this also comes with: Higher efficacy: Substantially greater weight loss More side effects: Increased GI symptoms and dysesthesia Unknown long-term effects: Retatrutide's extended safety profile is still being evaluated What's Next: The TRIUMPH Program Timeline TRIUMPH-4 is just the beginning

It is also worth noting that, consistent with other incretin-based and glucagon co-agonist therapies, small mean increases in heart rate were observed in the trial

Most suppliers ship lyophilized powder because it is more stable during shipping and storage